IFI-35 activators represent a specialized class of chemical compounds known for their ability to modulate the activity of the Interferon-Induced Protein 35 (IFI-35), a key player in the immune response. IFI-35, or Interferon-Induced Protein 35 kDa, is part of the family of interferon-induced genes (ISGs). These genes are activated in response to interferon signaling, a critical component of the innate immune system's antiviral defense. IFI-35, like other ISGs, is believed to be involved in various immune-related functions, although the precise mechanisms of its action are still under investigation. IFI-35 activators are meticulously designed to interact with IFI-35, influencing its function and potentially affecting its role in antiviral defense and immune modulation.
At the molecular level, the mechanisms underlying IFI-35 activation can be multifaceted. These activators may bind to specific regions of the IFI-35 protein, potentially inducing conformational changes that impact its interactions with other molecules within the immune signaling pathways. Research in the field of IFI-35 activators aims to elucidate the precise molecular mechanisms by which these compounds influence IFI-35 function and their downstream effects on the immune response. Understanding the role of IFI-35 activators contributes to our broader knowledge of immune system regulation and the intricate web of molecules involved in host defense against viral infections. These compounds serve as valuable tools for scientists seeking to investigate the molecular basis of interferon-induced gene activation and their implications in various immunological contexts, ultimately deepening our understanding of the immune system's role in antiviral defense.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Mimic of double-stranded RNA, a viral replication intermediate; activates interferon pathways, potentially upregulating IFI-35. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Toll-like receptor 7 agonist; can induce interferon pathways leading to potential upregulation of IFI-35. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Another TLR7 agonist; similar effects to Imiquimod. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
Toll-like receptor 4 agonist; activates innate immune response, potential influence on IFI-35 expression. | ||||||
2′,3′-cGAMP | 1441190-66-4 | sc-507484 | 10 mg | $1800.00 | ||
STING agonist; activates interferon pathways which might upregulate IFI-35. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
By inhibiting JAK, they modulate interferon signaling; could influence IFI-35 expression. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
ER stress inducer; might indirectly influence IFI-35 through unfolded protein response and associated signaling. | ||||||